AKBA241220P500
- 0.00
- 0.000.00%
Akebia Therapeutics Newsroom
Investors in Akebia Therapeutics (NASDAQ:AKBA) Have Unfortunately Lost 73% Over the Last Five Years
Express News | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Akebia Therapeutics Inc - Vafseo Expected to Be Available in U.S. in January 2025
Express News | U.S. Renal Care Enrolled First Patients in the Voice Collaborative Clinical Trial of Vafseo® (Vadadustat) for Ckd Patients on Dialysis
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo (Vadadustat) for CKD Patients on Dialysis
Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
US Manufacturing Index Rises To 43, Highest Since 2020
Akebia Therapeutics Announces That The American Journal Of Kidney Disease Has Published The Results Of FO2CUS, An Open-Label Study Evaluating The Efficacy And Safety Of Vadadustat, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, In...
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease
Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50
Akebia Therapeutics Prepares for Vafseo Launch
Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript Summary
Express News | Akebia Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Financial Results
Akebia GAAP EPS of -$0.10, Revenue of $37.4M
Akebia Therapeutics | 10-Q: Q3 2024 Earnings Report
Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q3 Revenue $37.4M
Akebia Therapeutics | 8-K: Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Express News | Akebia Therapeutics Q3 Operating Expenses USD 35.772 Million